The Food and Drug Administration expects an increase in the US supply of children’s OTC pain relievers due to the potential for a widespread jump in demand as consumers respond to concerns about seasonal flu, respiratory syncytial virus (RSV) and COVID-19.
A representative of the FDA’s Center for Drug Research and Evaluation told HBW Insight the agency “is working closely with numerous manufacturers and others in the supply chain to understand,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?